Leadership banner

LEADERSHIP

Leadership Team

The strength of our leadership team’s proven track record in the pharmaceutical space means we’re deeply experienced in every aspect of developing and delivering innovative treatments for serious and potentially life-threatening food, gastrointestinal (GI), and metabolic-related diseases - from research and development, to commercialization and manufacturing.

Andrew Oxtoby

Andrew Oxtoby

President & Chief Executive Officer

Jason Burdette

Jason Burdette

Senior Vice President, Head of Technical Operations

Nicolas Fouché

Nicolas Fouché

Senior Vice President, Head of International

Alicia Goodman

Alicia Goodman

Senior Vice President, Human Resources

Steve Killmeyer

Steve Killmeyer

Vice President, Head of Finance

Fabiana Lacerca-Allen

Fabiana Lacerca-Allen

Senior Vice President, Compliance

Cathy Nolan

Cathy Nolan

Senior Vice President, Strategy, Marketing & Innovation

Louise Peacock

Louise Peacock

Senior Vice President, Head of Pharma R&D

Jim Pepin

Jim Pepin

Senior Vice President and General Counsel

Moreno Perugini

Moreno Perugini

Senior Vice President, Global Medical Affairs

Paul Spence

Paul Spence

Senior Vice President, U.S. Pharmaceuticals

Doug Walker

Doug Walker

Senior Vice President, IT & Facilities

 

Andrew Oxtoby has over two decades of experience in the health care and consumer products industries, including extensive global pharmaceutical experience with successful product launches, commercialization, and strategic planning. Mr. Oxtoby joined Aimmune in January 2019 as Chief Commercial Officer and built the commercial organization to prepare for the FDA approval and launch of PALFORZIA in January 2020, transforming Aimmune from a clinical-stage organization to a fully integrated commercial-stage biotechnology company. In October 2020, Mr. Oxtoby was appointed President and Chief Executive Officer.

Before joining Aimmune, Mr. Oxtoby spent 16 years at Eli Lilly and Company where, after having served as Vice President of U.S. Diabetes Sales, he was responsible for Lilly’s U.S. insulin business as Vice President of U.S. Diabetes Connected Care and Insulins, an innovative, patient-focused business unit. While at Lilly, he also spent five years in oncology, including as Vice President of the International Oncology business, was General Manager of Lilly’s Netherlands operation, and held positions of increasing responsibility in marketing and sales. Mr. Oxtoby began his career at Procter & Gamble, where he spent four years in the engineering and manufacturing organizations. Mr. Oxtoby has a Master of Business Administration from Harvard Business School and a Bachelor of Science in Mechanical Engineering from Purdue University.

Jason is an experienced leader with more than 30 years in the pharmaceutical industry across process chemistry, formulation and process development, manufacturing, supply chain management, and technical operations. He joined Aimmune from Paratek Pharmaceuticals, where he was the Senior Vice President of Technical Operations. During his five years there, he was responsible for CMC, manufacturing and supply chain, manufacturing science and technology, analytical chemistry, and product distribution, and was an active member of Paratek’s executive leadership team.

Prior to Paratek, Jason was the Vice President of Supply Chain with Eagle Pharmaceuticals, Vice President of Supply Chain, where he led manufacturing, supply chain, distribution, and new product introduction.

Before Eagle Pharmaceuticals, Jason spent over 10 years with Shire Pharmaceuticals, holding positions of increasing responsibility including Vice President, Geographic Expansion Strategy and Planning, Interim Head of Product Strategy, Product Strategy Lead for Vyvanse, Adderall, and Equasym, and Global Product Director, Supply Chain Lead for the ADHD business. He was a member of the supply chain leadership team and the international commercial team among other key executive leadership teams.

Earlier in Jason’s career he worked with aaiPharma, Elan Pharmaceuticals, Sandoz and Mylan Pharmaceuticals. Jason holds a bachelor’s degree in Chemistry and an MBA from West Virginia University.

Nicolas Fouché has 21 years of pharmaceutical and biotechnology experience with the Boston Consulting Group (BCG), AstraZeneca, and most recently Gilead. He joined Aimmune in early 2020 as General Manager, France and U.K. to prepare for the launch of PALFORZIA; creating country teams and supporting reimbursement efforts before being promoted in December 2020 to his current position and undertaking the same launch activities across Europe and other geographies in order to bring PALFORZIA to patients worldwide.

Prior to Aimmune, Mr. Fouché’s career spanned positions in Marketing, Sales, Business Development, Strategic Planning, Business Operations and General Management; starting initially as an advisor to pharmaceutical companies at BCG, and then in-market positions in France, the U.K. and Japan, and regional roles across Europe, the Middle East and Africa (EMEA) and Central & Eastern Europe; overseeing dozens of launches of Gilead’s Hepatitis C and HIV medicines; and setting up infrastructures for patients to receive life-saving viral treatment. Mr. Fouché is French and holds a Master of Business Administration from Ecole Supérieure des Sciences Economiques et Commerciales (ESSEC).

Alicia Goodman has more than 30 years of experience in International and Strategic Human Resources Planning, Talent Acquisition and Development, and advancing organizational cultures in pharmaceutical and biotechnology, consumer goods, and telecommunications. Most recently, Ms. Goodman led the Human Resources function at Millendo Therapeutics, a biotechnology start-up focused on endocrine diseases. Other previous experience includes working as a principal in a human resources consultancy firm.

Previously, Ms. Goodman was with Novartis for six years, where she held several Human Resources roles of increasing responsibility in both Switzerland and the U.S., culminating with the position of Vice President of Human Resources for North America, in their Consumer Health division. Ms. Goodman holds a Master of Science in Human Resources from Central Michigan University and a Bachelor of Arts in Social Science from Michigan State University.

Prior to Aimmune, Steve spent over five years in the Deloitte Life Science M&A Finance practice where he worked with Fortune 500 clients on M&A growth strategy and integration. His integration work focused on standing up the core Finance infrastructure and processes for private equity acquisitions.

Prior to Deloitte, Steve worked as a healthcare investor at a startup private equity fund, HealthCor Partners, and as a healthcare investment banker at Merrill Lynch.

Steve holds a Master of Business Administration from The Wharton School at the University of Pennsylvania, and a Bachelor of Science in Finance from Carnegie Mellon University.

With over 28 years of experience in Compliance and Legal, Mrs. Lacerca-Allen has been a leader in developing and implementing global compliance programs within Top Fortune 100 companies. She has extensive experience delineating compliance strategy, leading global teams and negotiating, implementing, and executing on corporate integrity agreements, deferred prosecution agreements and consent decrees.

Mrs. Lacerca-Allen currently serves as a Board of Director Member at Shield Therapeutics, and The Center of Excellence in Life, and previously at ArthroCare Medical Corporation.

Prior to joining Aimmune Therapeutics, Mrs. Lacerca-Allen held several leadership positions at Elan Pharmaceuticals, Mylan Laboratories, Bristol Myers & Squibb, Microsoft, Merck Sharp & Dohme, AT&T Capital.

Mrs. Lacerca-Allen received her Juris Doctor degree from the Universidad de Buenos Aires and obtained her Master of Laws degree from University of California Los Angeles (UCLA) where she was the recipient of 1992 UCLA’s tuition waiver based on merit and recognition. She has been recognized by Compliance Week as Top Minds 2019, Hispanic Executive Magazine as Legal Industry Leader and by The Guardian as Women in Leadership, Inspiring Leaders among other recognitions.

Cathy Nolan has over two decades of experience in the pharmaceutical industry. Prior to joining Aimmune, Ms. Nolan spent 20 years at Eli Lilly and Company, where she was involved in commercial roles in small and large affiliates, global organizations in the U.S. and Europe, and most recently as a Business Unit Leader and Chief Marketing Officer in the U.K. Hub. Ms. Nolan has deep marketing and commercialization experience and expertise, leading brand building efforts for early phase products in the global organization as well as the commercialization of launch products through to late lifecycle across geographies.

Ms. Nolan joined Aimmune as the Executive Director of Global Marketing and Commercial Capabilities and has been a member of the team since November 2019. She has a Bachelor of Commerce Degree and a Higher Diploma in Marketing Practice from the National University of Ireland, Galway.

Louise Peacock has worked in the pharmaceutical industry for over 30 years, undertaking global strategic and operational leadership roles supporting product development, launch, and life cycle management activities for a variety of small molecule and biological products. Prior to joining Aimmune, Ms. Peacock sequentially held senior roles spanning regulatory affairs, development and GXP compliance in small biotech companies including Auxilium Pharmaceuticals, Intermune and Circassia. Prior to this she spent over 10 years in leadership roles of increasing seniority at Abbott Laboratories.

Ms. Peacock holds a Bachelor of Science degree in Pharmacology from Kings College, University of London, and a Bachelor of Laws degree from the University of West London. She is also a qualified Barrister (non-practicing).

Ms. Peacock joined Aimmune Therapeutics in June 2017 as Vice President, Regulatory Affairs & Quality Europe, and then took on the role of Senior Vice President, Global Regulatory Affairs & Head of Europe at the end of 2019. Following the acquisition of Aimmune Therapeutics by Nestlé Health Science, she assumed the role of Senior Vice President, Head of Global Pharma Regulatory Affairs, REMS, and Program Management before being promoted to her current role.

Jim Pepin has been practicing law for over 20 years, with significant experience in the life sciences and consumer goods industries. Prior to joining Aimmune, Mr. Pepin spent over 10 years with Nestlé HealthCare Nutrition, Inc., where he most recently served as its Vice President & General Counsel. As a member of the senior leadership team, he led the Legal & Compliance function of Nestlé’s U.S. healthcare nutrition business, which markets and sells a diverse portfolio of consumer care nutritional products as well as specialized medical nutrition sold directly to hospitals, long-term care facilities and home healthcare providers.

Prior to joining Nestlé in 2010, he was Acting General Counsel, Corporate Secretary and Compliance Officer of PDI, Inc., a publicly traded pharmaceutical contract sales organization. Mr. Pepin began his legal career as a corporate attorney at Sullivan & Cromwell LLP in London, England and then at King & Spalding LLP in New York, specializing in Corporate Finance and Securities Law. Mr. Pepin earned his Bachelor of Arts in Foreign Affairs from the University of Virginia and a Juris Doctor from the University of Virginia School of Law.

Moreno joined Nestle Health Science in 2015 as the leader of the Global Market Access team, and soon after the Global Medical Affairs teams. He played a key role in the creation of the Pharma division as VP of Marketing, Market Access and Medical Affairs for Zenpep, and more recently as US VP of Marketing & Commercial Operations for Aimmune. Prior to Nestle Health Science, Moreno was VP Health Technology Assessment for Sanofi - Aventis with the responsibility for assessing the clinical and economic evidence needed to successfully commercialize new technologies worldwide. Prior to his time with Sanofi, Moreno held roles of increasing responsibility across Evidence Generation, Market Access, and Early Commercialization in AbbVie, Lilly, Novartis and Pfizer.

Moreno holds an MBA from UCLA - Bocconi, a Masters in Public Health from University Pompeu Fabra, and is a certified Regulatory Professional. He is also currently the chair of a special interest group for the International Society of Pharmacoeconomics and Outcome Research.

Paul Spence has over 30 years of experience in the life science and pharmaceutical industry. Currently, Mr. Spence is the Senior Vice President of the U.S. Commercial organization for the Aimmune Gastrointestinal and Food Allergy businesses. In this role, he is ultimately responsible for the commercialization of PALFORZIA and ZENPEP, the eventual U.S., commercialization of Seres-109, and integrating the legacy U.S. Nestlé Health Science (NHSc) U.S. Pharmaceutical and Aimmune Pharmaceutical organizations and operations into the newly created Global Aimmune Pharmaceutical business unit.

Mr. Spence’s highly successful foundation is built upon U.S., and global roles in Marketing, Sales, Operations, Strategy and Commercial Leadership. Mr. Spence’s passions for building teams, launching new models and brands, leading organizational transformation, culture and talent development are central to his approach to leading teams and partnering cross-functionally.

Mr. Spence joined NHSc in 2016 as Vice President of Medical Nutrition Sales, where he transformed his sales leadership team with fast-paced growth initiatives and new go-to-market models. Previous to NHSc, he was with Boehringer-Ingelheim (BI), culminating with the position of Vice President of Sales, South Area. Prior to that he was Executive Director of the Go-to-Market model where he led BI’s national initiative to transform the U.S. medical and commercial customer-facing model to support BI’s long-range forecast, portfolio evolution and marketplace change. Before joining BI, Mr. Spence spent six years with Sanofi-Aventis, where he held several commercial roles. His other experience includes Marketing, Field Leadership, and Operations roles with Bristol-Myers Squibb and Johnson & Johnson.

Mr. Spence holds a Bachelor of Science in Finance and Accounting from The Pennsylvania State University and a Master of Business Administration from Villanova University. He also holds several certifications, including Six Sigma Green Belt and Loyola University Quality Institute.

Doug Walker has over 30 years of Information Technology (IT) leadership experience within pharmaceutical and biotechnology organizations.

Mr. Walker excels at building IT teams within organizations as they progress from pre-commercial Research & Development to full commercialization. Prior to joining Aimmune, Mr. Walker led IT at Ultragenyx and Ironwood Pharmaceuticals, and most recently held progressing IT leadership roles at GlaxoSmithKline over the span of 17 years.

Mr. Walker holds a Bachelor of Arts in Political Science from Westfield State University.